Work with thought leaders and academic experts in Cancer Research
Companies can greatly benefit from working with experts in the field of Cancer Research. These researchers bring a deep understanding of the disease and its mechanisms, allowing them to contribute valuable insights and expertise. Here are some ways companies can collaborate with academic researchers in Cancer Research: 1. Drug Discovery and Development: Academic researchers can assist in the discovery and development of new cancer drugs, providing expertise in target identification, preclinical testing, and clinical trials. 2. Biomarker Identification: Researchers can help identify biomarkers that can be used for early cancer detection, patient stratification, and monitoring treatment response. 3. Genomic Analysis: Experts in Cancer Research can analyze genomic data to identify genetic mutations and variations associated with cancer, enabling personalized treatment approaches. 4. Translational Research: Collaboration with academic researchers can facilitate the translation of basic research findings into clinical applications, bridging the gap between bench and bedside. 5. Clinical Trials: Companies can partner with academic researchers to conduct clinical trials, leveraging their expertise in trial design, patient recruitment, and data analysis. 6. Data Analytics: Researchers can apply advanced data analytics techniques to large-scale cancer datasets, uncovering patterns and insights that can inform treatment strategies. 7. Collaborative Research Projects: Joint research projects between companies and academic researchers can lead to innovative solutions and breakthrough discoveries in cancer treatment and prevention. 8. Education and Training: Academic researchers can provide educational programs and training to company employees, keeping them updated on the latest advancements in Cancer Research. 9. Intellectual Property: Collaboration with academic researchers can result in the generation of intellectual property, including patents and publications, which can enhance a company's competitive advantage. 10. Access to Networks and Resources: Academic researchers have access to extensive networks and resources, including collaborations with other experts, funding opportunities, and state-of-the-art facilities.
Researchers on NotedSource with backgrounds in Cancer Research include Ramy Ayoub, Gwendolyn Thomas, Ph.D., CSCS, USAW-L1, Dr. Michael W. Craige, PhD, MBA, Elena Shersher, Ph.D., Ping Luo, John M Baust, Ph.D, Dr. Everson A Nunes, Ph.D., Dr. Shilpa Patil, Ph.D, Elvira Forte, Dr. Lindsey Kuehm, Ph.D., and Boris Leibovitch.
Ramy Ayoub
PhD Medical Biophysics
Most Relevant Research Expertise
Other Research Expertise (10)
About
Most Relevant Publications (2+)
7 total publications
QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY
Neuro-Oncology / Jun 01, 2018
Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634
MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma
Neuro-Oncology / Jun 01, 2022
Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452
See Full Profile
Gwendolyn Thomas, Ph.D., CSCS, USAW-L1
Resistance Exercise Physiologist/Performance Enhancement/Optimizing RE Prescription
Most Relevant Research Expertise
Other Research Expertise (30)
About
Most Relevant Publications (4+)
51 total publications
Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation
BMC Cancer / Jan 22, 2019
van Rooijen, S., Carli, F., Dalton, S., Thomas, G., Bojesen, R., Le Guen, M., Barizien, N., Awasthi, R., Minnella, E., Beijer, S., Martínez-Palli, G., van Lieshout, R., Gögenur, I., Feo, C., Johansen, C., Scheede-Bergdahl, C., Roumen, R., Schep, G., & Slooter, G. (2019). Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. BMC Cancer, 19(1). https://doi.org/10.1186/s12885-018-5232-6
Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study
Cancer Prevention Research / Feb 01, 2013
Jones, S. B., Thomas, G. A., Hesselsweet, S. D., Alvarez-Reeves, M., Yu, H., & Irwin, M. L. (2013). Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study. Cancer Prevention Research, 6(2), 109–118. https://doi.org/10.1158/1940-6207.capr-12-0278
Trends in Diet and Cancer Research: A Bibliometric and Visualization Analysis
Cancers / Jul 25, 2023
Giles, E. D., Purcell, S. A., Olson, J., Vrieling, A., Hirko, K. A., Woodruff, K., Playdon, M. C., Thomas, G. A., Gilmore, L. A., Moberly, H. K., & Newell-Fugate, A. E. (2023). Trends in Diet and Cancer Research: A Bibliometric and Visualization Analysis. Cancers, 15(15), 3761. https://doi.org/10.3390/cancers15153761
Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities
JNCI Monographs / May 04, 2023
Gilmore, L. A., Parry, T. L., Thomas, G. A., & Khamoui, A. V. (2023). Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities. JNCI Monographs, 2023(61), 30–42. https://doi.org/10.1093/jncimonographs/lgad006
See Full Profile
Dr. Michael W. Craige, PhD, MBA
Entrepreneurial Scientist | Research Technology, Informatics & Data Science
Most Relevant Research Expertise
Other Research Expertise (5)
About
Most Relevant Publications (1+)
3 total publications
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Frontiers in Oncology / Sep 06, 2023
Ramakrishnan, A., Datta, I., Panja, S., Patel, H., Liu, Y., Craige, M. W., Chu, C., Jean-Marie, G., Oladoja, A.-R., Kim, I., & Mitrofanova, A. (2023). Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1222168
See Full Profile
Elena Shersher, Ph.D.
Cancer researcher at University of Miami
Most Relevant Research Expertise
Other Research Expertise (5)
About
Most Relevant Publications (2+)
4 total publications
Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells
Cancer Research / Apr 05, 2021
Alvarez-Trotta, A., Guerrant, W., Astudillo, L., Lahiry, M., Diluvio, G., Shersher, E., Kaneku, H., Robbins, D. J., Orton, D., & Capobianco, A. J. (2021). Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells. Cancer Research, 81(12), 3347–3357. https://doi.org/10.1158/0008-5472.can-20-3611
A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase
Molecular Therapy - Oncolytics / Mar 01, 2023
Diluvio, G., Kelley, T. T., Lahiry, M., Alvarez-Trotta, A., Kolb, E. M., Shersher, E., Astudillo, L., Kovall, R. A., Schürer, S. C., & Capobianco, A. J. (2023). A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase. Molecular Therapy - Oncolytics, 28, 307–320. https://doi.org/10.1016/j.omto.2023.02.008
See Full Profile
John M Baust, Ph.D
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Expertise
Other Research Expertise (16)
About
Most Relevant Publications (13+)
68 total publications
Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate
Technology in Cancer Research & Treatment / Apr 01, 2007
Baust, J. G., Gage, A. A., Klossner, D., Clarke, D., Miller, R., Cohen, J., Katz, A., Polascik, T., Clarke, H., & Baust, J. M. (2007). Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate. Technology in Cancer Research & Treatment, 6(2), 97–109. https://doi.org/10.1177/153303460700600206
Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death
Technology in Cancer Research & Treatment / Apr 01, 2007
Clarke, D. M., Robilotto, A. T., Rhee, E., VanBuskirk, R. G., Baust, J. G., Gage, A. A., & Baust, J. M. (2007). Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death. Technology in Cancer Research & Treatment, 6(2), 69–79. https://doi.org/10.1177/153303460700600203
Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques
Technology in Cancer Research & Treatment / Apr 01, 2007
Robilotto, A. T., Clarke, D., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2007). Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques. Technology in Cancer Research & Treatment, 6(2), 81–89. https://doi.org/10.1177/153303460700600204
Integrin involvement in freeze resistance of androgen-insensitive prostate cancer
Prostate Cancer and Prostatic Diseases / Jan 12, 2010
Baust, J. G., Klossner, D. P., VanBuskirk, R. G., Gage, A. A., Mouraviev, V., Polascik, T. J., & Baust, J. M. (2010). Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 13(2), 151–161. https://doi.org/10.1038/pcan.2009.59
Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model
Prostate Cancer and Prostatic Diseases / Jan 11, 2011
Santucci, K. L., Snyder, K. K., Baust, J. M., Van Buskirk, R. G., Mouraviev, V., Polascik, T. J., Gage, A. A., & Baust, J. G. (2011). Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer and Prostatic Diseases, 14(2), 97–104. https://doi.org/10.1038/pcan.2010.52
Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model
Prostate Cancer and Prostatic Diseases / Dec 11, 2012
Robilotto, A. T., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2012). Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model. Prostate Cancer and Prostatic Diseases, 16(1), 41–49. https://doi.org/10.1038/pcan.2012.48
Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue
Prostate Cancer and Prostatic Diseases / Jan 27, 2015
Baust, J. G., Bischof, J. C., Jiang-Hughes, S., Polascik, T. J., Rukstalis, D. B., Gage, A. A., & Baust, J. M. (2015). Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer and Prostatic Diseases, 18(2), 87–95. https://doi.org/10.1038/pcan.2014.54
Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation
Technology in Cancer Research & Treatment / Jun 23, 2016
Baumann, K. W., Baust, J. M., Snyder, K. K., Baust, J. G., & Van Buskirk, R. G. (2016). Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation. Technology in Cancer Research & Treatment, 16(4), 393–405. https://doi.org/10.1177/1533034616655658
Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer
Technology in Cancer Research & Treatment / Jul 08, 2016
Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2016). Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer. Technology in Cancer Research & Treatment, 15(4), 609–617. https://doi.org/10.1177/1533034616648059
Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model
Technology in Cancer Research & Treatment / May 17, 2017
Baust, J. M., Robilotto, A., Snyder, K. K., Santucci, K., Stewart, J., Van Buskirk, R., & Baust, J. G. (2017). Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model. Technology in Cancer Research & Treatment, 16(6), 900–909. https://doi.org/10.1177/1533034617708960
Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome
Technology in Cancer Research & Treatment / Jan 01, 2018
Baust, J. M., Rabin, Y., Polascik, T. J., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. Technology in Cancer Research & Treatment, 17, 153303381876220. https://doi.org/10.1177/1533033818762207
Cryoablation: physical and molecular basis with putative immunological consequences
International Journal of Hyperthermia / Nov 29, 2019
Baust, J. G., Snyder, K. K., Santucci, K. L., Robilotto, A. T., Van Buskirk, R. G., & Baust, J. M. (2019). Cryoablation: physical and molecular basis with putative immunological consequences. International Journal of Hyperthermia, 36(sup1), 10–16. https://doi.org/10.1080/02656736.2019.1647355
Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model
Breast Cancer: Basic and Clinical Research / Jan 01, 2020
Snyder, K. K., Van Buskirk, R. G., Baust, J. G., & Baust, J. M. (2020). Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model. Breast Cancer: Basic and Clinical Research, 14, 117822342097236. https://doi.org/10.1177/1178223420972363
See Full Profile
Dr. Everson A Nunes, Ph.D.
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Other Research Expertise (39)
About
Most Relevant Publications (6+)
97 total publications
Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats?
Nutrition and Cancer / Sep 21, 2016
Schiessel, D. L., Yamazaki, R. K., Kryczyk, M., Coelho de Castro, I., Yamaguchi, A. A., Pequito, D. C. T., Brito, G. A. P., Borghetti, G., Aikawa, J., Nunes, E. A., Naliwaiko, K., & Fernandes, L. C. (2016). Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats? Nutrition and Cancer, 68(8), 1369–1380. https://doi.org/10.1080/01635581.2016.1224364
Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer
Nutrition and Cancer / Dec 23, 2015
Camargo, C. de Q., Mocellin, M. C., Pastore Silva, J. de A., Fabre, M. E. de S., Nunes, E. A., & Trindade, E. B. S. de M. (2015). Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutrition and Cancer, 68(1), 70–76. https://doi.org/10.1080/01635581.2016.1115097
Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status
Nutrition and Cancer / Feb 24, 2015
Camargo, C. de Q., Borges, D. da S., Oliveira, P. F. de, Chagas, T. R., Del Moral, J. A. G., Durigon, G. S., Dias, B. V., Vieira, A. G., Gaspareto, P., Trindade, E. B. S. de M., & Nunes, E. A. (2015). Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutrition and Cancer, 67(3), 463–471. https://doi.org/10.1080/01635581.2015.1004732
Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats
Journal of Cancer Science & Therapy / Jan 01, 2014
Bordignon, J. (2014). Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats. Journal of Cancer Science & Therapy, 06(03). https://doi.org/10.4172/1948-5956.1000254
Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats
Nutrition and Cancer / Feb 01, 2012
Kuczera, D., Paro de Oliveira, H. H., Fonseca Guimarães, F. de S., de Lima, C., Alves, L., Machado, A. F., Coelho, I., Yamaguchi, A., Donatti, L., Naliwaiko, K., Fernandes, L. C., & Nunes, E. A. (2012). Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats. Nutrition and Cancer, 64(2), 286–293. https://doi.org/10.1080/01635581.2012.647229
Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats
Nutrition and Cancer / Nov 01, 2005
Pizato, N., Bonatto, S., Yamazaki, R. K., Aikawa, J., Nogata, C., Mund, R. C., Nunes, E. A., Piconcelli, M., Naliwaiko, K., Curi, R., Calder, P. C., & Fernandes, L. C. (2005). Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats. Nutrition and Cancer, 53(2), 194–201. https://doi.org/10.1207/s15327914nc5302_8
See Full Profile
Dr. Shilpa Patil, Ph.D
PhD & Postdoc level expertise in Cancer Research
Most Relevant Research Expertise
Other Research Expertise (11)
About
Most Relevant Publications (3+)
20 total publications
EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6
Cancer Research / Nov 01, 2020
Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., Versemann, L., Bösherz, M. S., Brunner, M., Gaedcke, J., Ströbel, P., Zhang, J.-S., Neesse, A., Ellenrieder, V., Singh, S. K., … Hessmann, E. (2020). EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Research, 80(21), 4620–4632. https://doi.org/10.1158/0008-5472.can-20-0672
TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer
Cancers / Jul 15, 2022
Versemann, L., Patil, S., Steuber, B., Zhang, Z., Kopp, W., Krawczyk, H. E., Kaulfuß, S., Wollnik, B., Ströbel, P., Neesse, A., Singh, S. K., Ellenrieder, V., & Hessmann, E. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Cancers, 14(14), 3451. https://doi.org/10.3390/cancers14143451
HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells
Cancers / Dec 07, 2021
Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Hessmann, E., & Dobbelstein, M. (2021). HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 13(24), 6163. https://doi.org/10.3390/cancers13246163
See Full Profile
Elvira Forte
Scientific strategist • Senior Scientist • Senior Scientific Editor
Most Relevant Research Expertise
Other Research Expertise (26)
About
Most Relevant Publications (2+)
63 total publications
EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids
Cancers / Jul 29, 2017
Forte, E., Chimenti, I., Rosa, P., Angelini, F., Pagano, F., Calogero, A., Giacomello, A., & Messina, E. (2017). EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids. Cancers, 9(12), 98. https://doi.org/10.3390/cancers9080098
Cardiac Cell Therapy: The Next (Re)Generation
Stem Cell Reviews and Reports / Mar 25, 2011
Forte, E., Chimenti, I., Barile, L., Gaetani, R., Angelini, F., Ionta, V., Messina, E., & Giacomello, A. (2011). Cardiac Cell Therapy: The Next (Re)Generation. Stem Cell Reviews and Reports, 7(4), 1018–1030. https://doi.org/10.1007/s12015-011-9252-8
See Full Profile
Boris Leibovitch
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Expertise
Other Research Expertise (8)
About
Most Relevant Publications (2+)
22 total publications
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics / Aug 01, 2015
Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t
Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1
Translational Oncology / Feb 01, 2022
Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320
See Full Profile
Example Cancer Research projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Cancer Research?
Development of Targeted Therapies
An academic researcher in Cancer Research can collaborate with a pharmaceutical company to develop targeted therapies for specific types of cancer. By leveraging their expertise in molecular biology and drug discovery, the researcher can contribute to the design and optimization of novel drugs that selectively target cancer cells while minimizing side effects.
Identification of Novel Biomarkers
A company specializing in diagnostic tools can collaborate with a Cancer Research expert to identify novel biomarkers for early cancer detection. The researcher can utilize their knowledge of cancer biology and molecular techniques to identify specific biomarkers that can be incorporated into diagnostic tests, enabling early intervention and improved patient outcomes.
Genomic Analysis for Personalized Medicine
By partnering with an academic researcher in Cancer Research, a biotech company can leverage genomic analysis to develop personalized medicine approaches. The researcher can analyze genomic data from patients to identify genetic mutations and variations that can inform treatment decisions, leading to more targeted and effective therapies.
Development of Immunotherapies
Collaboration between a pharmaceutical company and a Cancer Research expert can lead to the development of innovative immunotherapies. The researcher can contribute their knowledge of the immune system and cancer immunology to design and optimize immunotherapeutic approaches, enhancing the company's portfolio of cancer treatments.
Exploration of Combination Therapies
An academic researcher in Cancer Research can collaborate with a company to explore combination therapies for cancer treatment. By combining different drugs or treatment modalities, the researcher can help identify synergistic effects and optimize treatment regimens, potentially improving patient outcomes and expanding the company's treatment options.